# Biospecimens
That Come With Answers

Pre-characterized matched tissue and blood sets with integrated multi-omic data.

Sequenced. Annotated. Ready to analyze.

- Cancer Biomarker Discovery & Validation
- Liquid Biopsy Diagnostic Development
- Curated for Immuno-Oncology Research
- Data-rich Annotations
- Ethically Sourced, Clinically Relevant

Solid Tumor

FFPE Block

+

Serum

Double Spun Plasma (cfDNA + cfRNA)

Matched Tissue & Blood
**Sourced from indications driving liquid biopsy innovation**

- Frozen and FFPE tissues with matched plasma and serum
- Demographics, medical history, diagnosis, disease characterization, and more included
- IRB-approved and ethically sourced samples, consented and compliant with global regulations

MIRROR Cohort
The Tumors That Defined Precision Oncology, **Preserved**

Access tissue and biofluids from the donors who built TCGA and The Expression Project for Oncology (expO)
Apply today's tools to yesterday's discoveries (while supply lasts!)

>2,000 samples from 30+ indications

Cancer Type
- NSCLC: 101 (34.8%)
- Endometrial: 28 (9.7%)
- Breast: 24 (8.3%)
- Pancreatic: 20 (6.9%)
- Prostate: 18 (6.2%)
- Colorectal: 17 (5.9%)
- Thyroid: 16 (5.5%)
- <5% Others

PRECISION
for medicine ®

NGS-Characterized Biospecimens

Skip to discovery with pre-sequenced biospecimens

37K+ Samples   **10K+** Participants

NGS-Tissue

Pre-Characterized Using Industry-Trusted Panels

Fuel your research with oncology biospecimens characterized genome-wide via TruSight® Oncology 500 (TSO 500) and Oncomine Precision Assay (OPA).

What's Included:

- **Biospecimen sets** include tumor, normal, and adjacent tissues with H&E images and detailed characterization data

- **DNA Variant Calls** using widely trusted bioinformatic platforms, annotated for frequency, size, type, clinical classification, MSI, and more

- **Additional data** like demographic, surgical, stage, and clinical information included

Assay Type

- **OPA** (7,883 | 71.99%)
- **TSO500** (2,531 | 23.11%)
- **OPA & TSO500** (318 | 2.9%)
- **Clinical SOC NGS** (218 | 2%)

Variant	Count
BRAF:p.V600E	587
KRAS:p.G12D	405
PIK3CA:p.H1047R	374
KRAS:p.G12V	346
FGFR4:p.V550M	328
PIK3CA:p.E545K	325
KRAS:p.G12C	301
RET:p.G810S	260

NGS-Biofluids

- **NGS Characterization for Oncology:**
  2,000 biofluid samples from 750+ donors sequenced and annotated with volume and LDT results; includes genomic, transcriptomic, and epigenomic data for biomarker discovery

- **Material and Sample Types:**
  Buffy Coat, PAXgene RNA, Streck DNA/plasma, EDTA plasma, serum, urine, saliva, CSF, and synovial fluid—collected via FDA-registered donor center and global network

- **Indications and Disease Categories:**
  Covers 50+ oncology and disease categories

- **Demographics, Stage, and Ethical Sourcing:**
  IRB-approved, ethically sourced specimens with detailed demographics

Material Type

- **Streck Buffy Coat** (723 | 24.3%)
- **Steck DNA Plasma** (569 | 19.13%)
- **PAXgene** (504 | 16.94%)
- **PAXgene RNA WB** (402 | 13.51%)
- **Streck Plasma** (281 | 9.45%)
- **Steck DNA Buffy Coat** (264 | 8.87%)
- **K2 EDTA Plasma** (182 | 6.12%)
- **Buffy Coat** (50 | 1.68%)

Indication	Count
Lung (NSCLC)	144
Breast	130
Prostate	72
Ovarian	53
Colon/Rectum	48
Colon	42
Rectal	38
Pancreatic	30
Breast Cancer	29
Esophageal	19
Melanoma	18
Lung Cancer	17

Build Your Cohort

Use our interactive platform to filter by indication, biomarker status, treatment history, and more at **precisionformedicine.com**

Download your digital copy

PRECISION for medicine®